Mrp2 is involved in the efflux and disposition of fosinopril

Journal of Applied Toxicology

Volumn 33, Issue 6, 2013, Pages 458-465

  Green, Benjamin R ^a,b   Bain, Lisa J ^a  

^a CLEMSON UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

ABC transporter; Drug drug interaction; Fosinopril; Methotrexate; Multidrug resistance associated protein 2

Indexed keywords

DESLORATADINE; FOSINOPRIL; LORATADINE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 2; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG HALF LIFE; EFFUSION; INTESTINE; KIDNEY; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERUM; WILD TYPE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; CELL SURVIVAL; DOGS; DRUG INTERACTIONS; FOLIC ACID ANTAGONISTS; FOSINOPRIL; HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; METHOTREXATE; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; TISSUE DISTRIBUTION;

MUS;

EID: 84876718127     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1767     Document Type: Article

References (42)

1. Amini H, Ahmadiani A. 2004. Rapid determination of loratadine in small volume plasma samples by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 809: 227-230.
2. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B. 2000. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol. 57: 760-768.
3. Bandler PE, Westlake CJ, Grant CE, Cole SPC, Deeley RG. 2008. Identification of regions required for apical membrane localization of human multidrug resistance protein 2. Mol. Pharmacol. 74: 9-19.
4. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD. 2002. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62: 3144-3150.
5. Chou JW, Yu CJ, Chuang PH, Lai HC, Hsu CH, Cheng KS, Peng CY, Chiang IP. 2008. Successful treatment of fosinopril-induced severe cholestatic jaundice with plasma exchange. Ann. Pharmacother. 42: 1887-1892.
6. Chu X, Strauss JR, Mariano MA, Li J, Newton DJ, Cai X, Wang RW, Yabut J, Hartley DP, Evans DC, Evers R, 2006. Characterization of mice lacking the multidrug resistance protein Mrp2 (Abcc2). J. Pharmacol. Exp. Ther. 317: 579-589.
7. Cui S, Feng F, Ma M, Liu H, Chen Y. 2007. Development and validation of liquid chromatography-tandem mass spectrometric method for simultaneous determination of fosinopril and its active metabolite fosinoprilat in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 854: 143-151.
8. de Graaf D, Sharma RC, Mechetner EB, Schimke RT, Roninson IB. 1996. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc. Natl Acad. Sci. USA 93: 1238-1242.
9. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. 2007. Interaction of non-steroidal anti-inflammatory drugs with MRP2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther. 320: 229-235.
10. El-Sherbiny DT, El-Enany N, Belal FF, Hansen SH. 2007. Simultaneous determination of loratadine and desloratadine in pharmaceutical preparations using liquid chromatography with a microemulsion as eluent. J. Pharm. Biomed. Anal. 43: 1236-1242.
11. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, Borst P. 1998. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 101: 1310-1319.
12. Fuksa L, Brcakova E, Kolouchova G, Hirsova P, Hroch M, Cermanova J, Staud F, Micuda S. 2010. Dexamethasone reduces methotrexate biliary elimination and potentiates its hepatotoxicity in rats. Toxicology 267: 165-171.
13. Ishizuka H, Konno K, Naganuma H, Sasahara K, Kawahara Y, Niinuma K, Suzuki H, Sugiyama Y. 1997. Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). J. Pharmacol. Exp. Ther. 280: 1304-1311.
14. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D. 1996. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 56: 988-994.
15. Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchell B, Keppler D. 1997. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem. J. 327: 305-310.
16. Keppler D, Konig J. 1997. Expression and localizaion of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J. 11: 509-516.
17. Kirschbaum J, Noroski J, Cosey A, Mayo D, Adamovics J. 1990. High-performance liquid chromatography of the drug fosenopril. J. Chromatogr. 507: 165-170.
18. Kruh GD, Belinsky MG, Gallo JM, Lee K. 2007. Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice. Cancer Metastasis Rev. 26: 5-14.
19. Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, Pang KS. 2006. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J. Pharmacol. Exp. Ther. 318: 395-402.
20. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y. 2005. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J. Pharmacol. Exp. Ther. 314: 1059-1067.
21. Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H, Sugiyama Y. 2008. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol. Pharmacol. 73: 1474-1483.
22. Murdoch D, McTavish D. 1992. Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. Drugs 43: 123-140.
23. Nunes AC, Amaro P, Maç as F, Cipriano A, Martins I, Rosa A, Pimenta I, Donato A, Freitas D. 2001. Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report. Eur. J. Gastroenterol. Hepatol. 13: 279-282.
24. Ondetti MA. 1988. Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation 77: I74-I78.
25. Oswald S, Giessmann T, Luetjohann D, Wegner D, Rosskopf D, Weitschies W, Siegmund W. 2006. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin. Pharmacol. Ther. 80: 477-485.
26. Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P. 2008. Prediction and identification of drug interactions with the human ATP-binding cassette transporter Multidrug-Resistance Associated Protein 2 (MRP2; ABCC2). J. Med. Chem. 51: 3275-3287.
27. Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y. 2004. Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. J. Pharmacol. Exp. Ther. 310: 648-655.
28. Stride BD, Valdimarsson G, Gerlach JH, Wilson GM, Cole SPC, Deeley RG. 1996. Structure and expression of the messenger RNA encoding the murine multidrug resistance protein, an ATP-binding cassette transporter. Mol. Pharmacol. 49: 962-971.
29. Suzuki H, Kawaratani T, Shioya H, Uji Y, Saruta T. 1993. Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans. Biopharm. Drug Dispos. 14: 41-50.
30. Takada Y, Tachizawa H, Kurihara H, Takayanagi M, Sasamoto T, Akashi M, Aiso M, Takamori Y, Sano N, Takikawa H. 2004. Comparison of urinary excretion of pravastatin and temocapril in bile duct-ligated rats and Eisai hyperbilirubinemic rats (EHBR). J. Hepatobiliary Pancreat. Surg. 11: 125-128.
31. Todd P, Levison D, Farthing MJ. 1990. Enalapril-related cholestatic jaundice. J. R. Soc. Med 83.4: 271-272.
32. Vlaming MLH, Mohrmann K, Wagenaar E, de Waart DR, Oude Elferink RPJ, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JHM, Schinkel AH. 2006. Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J. Pharmacol. Exp. Ther. 318: 319-327.
33. Vlaming ML, Pala Z, van Esch A, Wagenaar E, van Tellingen O, de Waart DR, Oude Elferink RP, van de Wetering K, Schinkel AH. 2008. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin. Cancer Res. 14: 8152-8160.
34. Vlaming ML, van Esch A, Pala Z, Wagenaar E, van de Wetering K, van Tellingen O, Schinkel AH. 2009. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol. Cancer Ther. 8: 3350-3359.
35. Vlaming ML, van Esch A, van de Steeg E, Pala Z, Wagenaar E, van Tellingen O, Schinkel AH. 2011. Impact of Abcc2 [multidrug resistance-associated protein (mrp) 2], abcc3 (mrp3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexte. Drug Metab. Dispos. 39: 1338-1344.
36. Wang Z, Zhou Q, Kruh GD, Gallo JM. 2011. Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab. Dispos. 39: 2155-2161.
37. Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, van der Born K, de Haas M, van der Heijden I, Kaspers G, Wijnholds J, Jansen G, Peters G, Borst P. 2005. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 65: 4425-4430.
38. Wijnholds J, Evers R, van Leusden MR, Mol CAAM, Zaman GJR, Mayer U, Beijnen JH, van der Valk M, Krimpenfort P, Borst P. 1997. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat. Med. 3: 1275-1279.
39. Wijnholds J, Scheffer GL, van der Valk M, van der Valk P, Beijnen JH, Scheper RJ, Borst P. 1998. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J. Exp. Med. 188: 797-808.
40. Williams GC, Liu A, Knipp G, Sinko PJ. 2002. Direct evidence that saquinavir is transported by Multidrug Resistance-Associated Protein (MRP1) and canalicular Multispecific Organic Anion Transporter (MRP2). Antimicrob. Agents Chemother. 46: 3456-3462.
41. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. 2001. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 61: 7225-7232.
42. Zimmermann C, van de Wetering K, van de Steeg E, Wagenaar E, Vens C, Schinkel AH. 2008. Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metab. Dispos. 36: 631-640.